Venus Medtech (Hangzhou) Inc
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to tre… Read more
Venus Medtech (Hangzhou) Inc (VMTHF) - Total Liabilities
Latest total liabilities as of June 2025: $1.05 Billion USD
Based on the latest financial reports, Venus Medtech (Hangzhou) Inc (VMTHF) has total liabilities worth $1.05 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Venus Medtech (Hangzhou) Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Venus Medtech (Hangzhou) Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Venus Medtech (Hangzhou) Inc Competitors by Total Liabilities
The table below lists competitors of Venus Medtech (Hangzhou) Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tudor Gold Corp
PINK:TDRRF
|
USA | $16.81 Million |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
China | CN¥109.88 Million |
|
SNP Schneider-Neureither & Partner SE
XETRA:SHF
|
Germany | €178.52 Million |
|
Hume Industries Berhad
KLSE:5000
|
Malaysia | RM424.37 Million |
|
Rumere Co. Ltd.
SHE:301088
|
China | CN¥59.55 Million |
|
Taita Chemical Co Ltd
TW:1309
|
Taiwan | NT$3.08 Billion |
|
ACT Energy Technologies Ltd.
TO:ACX
|
Canada | CA$208.70 Million |
|
Domo Inc
NASDAQ:DOMO
|
USA | $393.54 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Venus Medtech (Hangzhou) Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Venus Medtech (Hangzhou) Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Venus Medtech (Hangzhou) Inc (2017–2024)
The table below shows the annual total liabilities of Venus Medtech (Hangzhou) Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.04 Billion | -30.49% |
| 2023-12-31 | $1.49 Billion | -9.52% |
| 2022-12-31 | $1.65 Billion | +245.79% |
| 2021-12-31 | $477.61 Million | +3.56% |
| 2020-12-31 | $461.19 Million | +3630.72% |
| 2019-12-31 | $12.36 Million | -97.81% |
| 2018-12-31 | $564.01 Million | +399.95% |
| 2017-12-31 | $112.81 Million | -- |